Home Blood Transfusions
Launched by THOMAS JEFFERSON UNIVERSITY · Aug 12, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to give blood transfusions to patients with certain blood cancers or bone marrow problems who need regular transfusions. Instead of coming into the hospital, patients in this study will receive their transfusions safely at home. The goal is to see if home transfusions are practical and if patients find them acceptable and convenient.
To join the study, participants must be adults who need at least two blood transfusions every month, have no history of bad reactions to transfusions, and live within 30 miles of the hospital. They must also be willing to have healthcare workers visit their home. During the study, patients will receive between one and five units of blood products at home, and researchers will collect information about any challenges or concerns. This study is currently recruiting participants and aims to make treatment easier and more comfortable for patients who depend on blood transfusions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
- • Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study
- • Male or female, over the age of 18
- • Must meet definition of transfusion dependence (require at least 2 blood product transfusions over a 28-day period)
- • Receive their cancer care at SKCCC
- • Have a history of blood product transfusions and NO history of transfusion reactions,
- • Live within a 30-mile range of the Center City SKCCC location.
- • Must be willing to allow people into the home
- Exclusion Criteria:
- * An individual who meets any of the following criteria will be excluded from participation in this study:
- • Patients who have a history of a transfusion reaction
- • Heart failure as defined by AHA stage C or NYHA Class II-IV
- • Non-English or Spanish speaking
- • Are unhoused
- • Are incarcerated
- • Have poor venous access
- • Diagnosis of Solid Tumor malignancy
- • Women who are pregnant
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported